The chemotherapeutic agents 2'-deoxy-5-azacytidine (DAC) and cisplatin (cDDP) have been shown in vitro to be synergystic in their cytotoxicity toward human tumour cells. We have investigated possible molecular mechanisms underlying this synergy using the plasmid pSVE3 in vitro and after transfection into CMT3 cells. Increased binding of cDDP to DAC-substituted DNA generated in vivo was confirmed by flameless atomic absorption spectrophotometry (FAAS). The Many factors are considered when selecting the drugs to be included in a regimen of combination chemotherapy. Frequently, agents are chosen based on toxicity profiles and demonstrated efficacy in clinical trials. Occasionally, in vitro cytotoxicity assays will suggest a synergistic interaction (i.e. the effect of the two drugs together is greater than the predicted additive effect), and this information can be used in designing treatment protocols. Previous studies from our laboratory, using human tumour cell lines, showed that synergistic cytotoxicity can be demonstrated between 2'-deoxy-5-azacytidine (DAC) and cis-dichlorodiaminoplatinum (cDDP) (Frost et al., 1990) . The mechanism for synergy between cDDP and DAC remains to be elucidated. Theoretically, synergy between two drugs can occur at several cellular levels. One drug may increase cellular uptake of a second drug, or inhibit its removal from the cell. Metabolism of the second drug could be altered in a way that the drug persists in an active form for a longer time. For compounds that act at the level of DNA, incorporation or binding may be enhanced. The synergistic interaction between cDDP and DAC may likely take place at the DNA level, as this is where both drugs are known to exert their effects. cDDP binds directly to DNA, producing both intrastrand and interstrand crosslinks (Bird, 1978; Caradona et al., 1982; Pinto & Lippard, 1985) . The intrastrand crosslinking is most frequent at N7 of adjacent guanosines. DAC is an analog of deoxycytidine, substituting a nitrogen for carbon 5 of the pyrimidine ring. DAC is incorporated into DNA (Vesely & Cihak, 1977) and functions as a DNA methyltransferase inhibitor (Creusot et al., 1982) . The resulting DNA hypomethylation has been shown to be associated with changes in gene expression and cell differentiation (Jones & Taylor, 1980; Razin & Riggs, 1980 
Summary
The chemotherapeutic agents 2'-deoxy-5-azacytidine (DAC) and cisplatin (cDDP) have been shown in vitro to be synergystic in their cytotoxicity toward human tumour cells. We have investigated possible molecular mechanisms underlying this synergy using the plasmid pSVE3 in vitro and after transfection into CMT3 cells. Increased binding of cDDP to DAC-substituted DNA generated in vivo was confirmed by flameless atomic absorption spectrophotometry (FAAS). The plasmid used in these experiments was unmethylated suggesting that DAC was effective in enhancing cDDP binding to DNA without acting as a hypomethylating agent, but by directly changing the topology of DNA. The role of DNA methylation in cDDP binding was studied using methylated and unmethylated plasmid incubated in vitro with cDDP. Restriction analyses and FAAS measurement of bound platinum indicated that methylated DNA bound more cDDP than unmethylated DNA. In addition, in vivo studies confirmed the in vitro observations since replication of methylated plasmid was inhibited to a greater extent than unmethylated plasmid.
Many factors are considered when selecting the drugs to be included in a regimen of combination chemotherapy. Frequently, agents are chosen based on toxicity profiles and demonstrated efficacy in clinical trials. Occasionally, in vitro cytotoxicity assays will suggest a synergistic interaction (i.e. the effect of the two drugs together is greater than the predicted additive effect), and this information can be used in designing treatment protocols. Previous studies from our laboratory, using human tumour cell lines, showed that synergistic cytotoxicity can be demonstrated between 2'-deoxy-5-azacytidine (DAC) and cis-dichlorodiaminoplatinum (cDDP) (Frost et al., 1990) . The mechanism for synergy between cDDP and DAC remains to be elucidated. Theoretically, synergy between two drugs can occur at several cellular levels. One drug may increase cellular uptake of a second drug, or inhibit its removal from the cell. Metabolism of the second drug could be altered in a way that the drug persists in an active form for a longer time. For compounds that act at the level of DNA, incorporation or binding may be enhanced. The synergistic interaction between cDDP and DAC may likely take place at the DNA level, as this is where both drugs are known to exert their effects. cDDP binds directly to DNA, producing both intrastrand and interstrand crosslinks (Bird, 1978; Caradona et al., 1982; Pinto & Lippard, 1985) . The intrastrand crosslinking is most frequent at N7 of adjacent guanosines. DAC is an analog of deoxycytidine, substituting a nitrogen for carbon 5 of the pyrimidine ring. DAC is incorporated into DNA (Vesely & Cihak, 1977) and functions as a DNA methyltransferase inhibitor (Creusot et al., 1982) . The resulting DNA hypomethylation has been shown to be associated with changes in gene expression and cell differentiation (Jones & Taylor, 1980; Razin & Riggs, 1980 
Materials and methods

Plasmid preparation
The plasmid pSVE3 (Hartman et al., 1982) , was isolated from E. coli DH5 cells (Hanahan, 1983) using the alkaline extraction method followed by CsCl density centrifugation and extensive dialysis as previously described (Sambrook et al., 1989) .
Cells and culture conditions CMT3 cells (Gerard & Gluzman, 1985) were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY) supplemented with L-glutamine (292 yg ml-'), penicillin (500 U ml-1), streptomycin sulphate (100 fig ml-' Then, 400 jil of a solution of 100 ftl proteinase K (1 mg ml-') in 2 ml of a buffer containing 40 mM Tris. HCI (pH 7.5) 0.5% sodium dodecyl sulfate, 10 mM EDTA was added to each well. After gentle mixing the cell lysate was removed to 1.5 ml centrifuge tubes and incubated at 37°C for one hour. The suspension was then extracted twice with one volume of phenol:chloroform (1:1), precipitated with 0.3 M Na acetate and three volumes of ethanol, and resuspended in 200 fil H20. Two 50 IA aliquots were added to separate filter paper discs (sets B and C). To a third 50 gLl aliquot, 1OM NaOH was added to a final concentration of 0.5 M. After a 30 min incubation at 37°C, the NaOH treated samples were applied to filter paper discs (set D). (Chernajovsky, 1989) . On the following day, the cells were osmotically shocked for 4 min with 1 ml DMEM containing 10% glycerol, and washed with serum-free media. Five ml of fresh media were then added. DAC (Pharmachemie B.V., Haarlem, Netherlands) was prepared fresh in water as a stock solution of 2.1 mM. cDDP was prepared immediately prior to use as a stock solution of 3.3 mM in a buffer of 3 mM NaCl, 1 mM NaH2PO4, pH 7.5 (Ushay et al., 1981) . The drugs were added directly to the cell culture media to the final concentrations stated in the figure legends. If both drugs were used, DAC was added first followed 2 h later by cDDP. All drug treatments were performed at 37°C for 48 h.
Extraction, purification, quantitation and labelling of episomal DNA from CMT3 cells After transfection and incubation with the drug(s), episomal DNA was extracted from CMT3 cells using a modification of the method described by Hirt (Hirt, 1967 (Southern, 1975) using alkaline conditions (Chomczynski & Qasba, 1984) . Hind III digested pSVE3 DNA was labeled with a[32P] dCTP by random priming (Feinberg & Vogelstein, 1983) . Nytran filters were hybridised and washed as recommended by the supplier. Filters were exposed to autoradiography at -70°C with Kodak XAR-5 film, using intensifier screens.
Binding of cDDP to pSVE3 in vitro All in vitro incubations of cDDP with plasmid DNA were performed overnight at 37°C. A stock solution of 3.3 mM cDDP was prepared in a buffer containing 3 mM NaCl, 1 mM NaH2PO4, pH 7.5, as described (Ushay et al., 1981 The effect of DAC substitution of cDDP binding to DNA cDDP has been shown to inhibit replication of viral SV40 DNA (Cicarelli et al., 1985) . If DAC interacts with cDDP at the DNA level, it would be anticipated that DAC-substituted viral SV40 DNA would bind more cDDP. To study this potential interaction we used the 5.3 Kb eukaryotic vector pSVE3 (Hartman et al., 1982) , which contains the SV40 origin of replication and early genes in a 3.3 Kb viral DNA fragment (Figure 1) . The remaining 2.0 Kb of plasmid DNA is derived from pBR322 and contains numerous GC-rich regions, included in Hpa II and Hha I restriction sites. CMT3 cells, a simian cell line derived from CV-1 cells (Gerard & Gluzman, 1985) , were used for transfection studies. CMT3 cells constitutively produce a low level of T antigen so that when pSVE3 is transfected into this cell line, it replicates and is maintained episomally (Gerard & Gluzman, 1985) .
To demonstrate that the effect on plasmid replication was actually a function of increased cDDP binding to DACtreated DNA, we transfected CMT3 cells with pSVE3, and treated half of the plates with 1 JAM DAC. DAC-substituted and unsubstituted episomal DNA was isolated and incubated in vitro with 26.5 JAM cDDP overnight. cDDP binding was quantitated by FAAS. The increased binding of cDDP to DAC-treated DNA is shown in Table II .
The plasmid DNA used in these experiments was unmethylated. This minimised the possibility of DAC producing its effects through DNA hypomethylation. However, since hypomethylation is a well established DAC-induced alteration in DNA, we proceeded to investigate the role of methylation and hypomethylation on the binding of cDDP to DNA.
DNA methylation and cDDP binding in vitro When cDDP is bound to DNA at a restriction site, digestion by the specific endonuclease is inhibited (Ushay et al., 1981 methylated DNA at both Hha I and Hpa II sites. Linearised pSVE3 DNA, unmethylated (lanes 1-3 and 7-9) or methylated at Hha I sites (lanes 4-6 and 10 -12), was treated with restriction endonucleases after incubation with cDDP (lanes 7 -12) or no drug exposure (lanes 1-6). Restriction enzymes include Hpa II (lanes 1, 4, 7, 10); Msp I (lanes 2, 5, 8, 11); and Hha I (lanes 3, 6, 9, 12). Inhibition of restriction is seen in cDDP-treated methylated DNA at sites distant from the methylation site. Lane M contains a molecular weight marker (A phage DNA digested with Hind III).
Finally, we incubated 3 jig of either Hpa II methylated or unmethylated pSVE3 overnight with 26.5ylM CDDP. After removing unbound cDDP and buffer, samples were analyzed for bound platinum by FAAS. Table III shows the increase in platinum bound to methylated DNA compared to unmethylated DNA.
Discussion
We have attempted to elucidate the mechanism underlying the synergistic cytotoxocity between DAC and cDDP. We first demonstrated that labeled DAC is taken up by CMT3 cells and incorporated into DNA. Surprisingly, we also detected incorporation of DAC into RNA. DAC has been shown to be uniquely incorporated into DNA in human colon carcinoma cells (Glazer & Knode, 1984) . However, different cell types are capable to metabolise DAC in different ways. For example the block in colony forming activity, caused by DAC, can be relieved either with cytidine or deoxycytidine in HeLa cells (Snyder & Lachmann, 1989) but only with deoxycytidine in B16 melanoma cells (Cortvrindt et al., 1987) and human leukaemic progenitor cells (Bhalla et al., 1987) . In addition, the activity of the enzyme cytidine deaminase, which converts cytidine into uridine, was shown to be increased in HL-60 cells after treatment with DAC (Momparler & Laliberte, 1990) . These studies suggest that DAC can be shunted into the RNA pool as we have found.
We showed that in the presence of cDDP, there is de- been expected. We also showed that in vivo DAC substituted DNA bound more cDDP than unsubstituted DNA. This result was confirmed by direct measurements of bound platinum by FAAS, after incubating cDDP with DAC-substituted and unsubstituted DNA. These results suggest that the interaction between the two drugs takes place at the DNA level, the role of DAC being to increase the amount of bound cDDP. In these experiments, inhibition of DNA synthesis is the observed outcome of cDDP binding; however, one could predict that gene transcription might also be affected.
We attempted to clarify the role of DAC is this enhancement of cDDP binding. DAC is well know for its role in DNA hypomethylation. During DNA replication, DAC is incorporated as a cytosine analog into the newly synthesised strand. The parent strand remains methylated; however, in the presence of DAC, the action of methyltransferase is inhibited and the daughter strand is therefore unmethylated (Cruesot et al., 1982) . Because methylation of a daughter strand requires prior methylation of the parent strand, subsequent round of DNA synthesis after DAC substitution result in generally hypomethylated DNA (Bird, 1978) . It would seem possible, then, that DAC-induced hypomethylation might reveal additional cDDP binding sites, particularly in GC-rich regions such as occur frequently in eukaryotic promotors and other regulatory sites. In favour of such suggestion is the observation that increased protein binding to DNA was found at hemymethylated sites after DAC treatment (Michalowsky & Jones, 1987) ; since cDDP crosslinks both proteins and DNA (Ciccarelli et al., 1985) such sites could provide for an excellent substrate for cDDP binding. However, against this explanation is the fact that we were able to demonstrate synergy between DAC and cDDP in a system where further hypomethylation could not occur, i.e. by using a plasmid substrate that was already unmethylated. Yet, the possibility that DAC itself increases protein binding to DNA can not be ruled out.
The lack of enhancement of cDDP binding to hypomethylated DNA was subsequently shown by FAAS, restriction analysis, and in vivo DNA replication studies comparing cDDP-treated methylated and unmethylated plasmid DNA. In fact, methylated DNA is found in all three experimental systems to bind more cDDP than unmethylated DNA. This has led us to conclude that the role of DAC in enhancing cDDP binding to DNA is independent of its role as a hypomethylating agent. This is consistent with the results of Frost et al., who were unable to correlate the degree of DAC/cDDP synergy in cytotoxicity assays with the extent of DNA hypomethylation (Abbruzzesse & Frost, 1992; Frost et al., 1990) .
The enhancement of cDDP binding to methylated DNA was surprising. Methylation of cytosines is thought to play a role in regulation of gene function (Jones & Taylor, 1980) and transcriptionally active mammalian genomic DNA is frequently hypomethylated (Sanford et al., 1985) . Methylation of cytosines in GC-rich sequences in promoter regions may inhibit binding of RNA polymerase or other regulatory proteins, as the methyl group extends into the major groove (Razin & Riggs, 1980) . The role of the methyl group may simply be to produce steric hindrance. Alternatively, topologic changes may be involved. Stretches of alternating purines and pyrimidines are known to adopt the unusual left-handed Z DNA conformation (Wang et al., 1982) and this topologic form is stabilised by methylation of cytosines (Behe & Felsenfeld, 1981) . Methylation of a critical promotor region may produce or stabilise a DNA conformation that is no longer recognised by the transcriptional machinery.
In a similar manner, the conformation adopted by methylated DNA may actually make it more accessible to cDDP. This would predict that cDDP binding should be enhanced not only at the precise methylation site, but also for a distance upstream and downstream. The restriction studies described in Figures 2 and 3 show exactly this effect. In Figure 2 it is apparent that methylation of Hpa II sites has resulted in enhanced cDDP binding not only to Hpa II but also Hha I sites, as evidenced by incomplete restriction with both enzymes. Conversely, methylation of Hha I sites and treatment with cDDP limits restriction at Hpa II sites (Figure 3 ). We would propose, then, that certain conformations of DNA are more amenable to cDDP binding, and that one of these conformations is produced when short stretches of repetitive GC sequences are methylated.
In view of the above findings with methylated and unmethylated DNA, it is interesting to speculate about possible mechanisms for the enhancement of cDDP binding to DAC-substituted DNA. It appears that hypomethylation is not necessary for DAC to produce this effect. An alternative suggestion is that DAC incorporation into DNA might induce topologic changes that allow for an increase in cDDP binding, similar to the observation with methylated DNA. Unfortunately, DAC substituted DNA has not been analysed by X-ray crystallography, and therefore direct evidence for DAC-induced DNA conformational changes is lacking. However, some indirect evidence does exist. Jones and Taylor (Jones & Taylor, 1980) have shown than an approximate 5% substitution of 5-azacytidine for cytidine resulted in 80-85% inhibition of cytidine methylation. This suggests that the incorporated azanucleotide produces an effect distant from its immediate surroundings, similar to that which we have seen in our restriction studies using cDDP-treated methylated DNA. Furthermore, DAC-substituted genomic DNA con-tains fragile sites (Djalali et al., 1990) , and is more labile to single stand cleavage in alkali (D'Incalci et al., 1985) . Marked alterations in the chromosome structure and condensation patterns of DNA from GH12C, rat pituitary cells treated with 5-azacytidine have been reported by Parrow et al., (Parrow et al., 1989) . Additionally, the free azanucleotide is able to attain different tautomeric forms (Saenger, 1984) .
Future studies might be detected towards addressing the interesting possibility that DNA topologic alterations might occur secondary to DAC incorporation. Insight could be gained into the role of this compound as a hypomethylation agent, a differentiation agent, and a cancer chemotherapeutic drug.
